BioCina, an Australia-based contract development and manufacturing organization (CDMO), announced on Wednesday that it has received AUD5m grant under the Federal Government's Medical Research Future Fund (MRFF) Grants scheme to fund work with its industry partners to develop enabling technologies for production of precision mRNA vaccines.

Outcomes of this grant will extend mRNA manufacturing and analytical capabilities of BioCina's GMP facility to all clinical phases and commercial supply and deliver new to market automated microfluidics technology for manufacture of mRNA therapeutic vaccines, which will fill a significant technology gap in the personalised mRNA vaccines market.

The grant has been awarded by the Australian Government's National Health and Medical Research Council (NHMRC), and will be matched by the South Australian Government to support a five-year collaborative project with a total value of over AUD10.0m, working with industry and academic partners, Cytiva and the University of Adelaide.

The project, commencing almost immediately, helps BioCina address the post-pandemic mRNA demand for specific and essential attributes of new personalised RNA products.

(USD1=AUD1.51)